Optimizing the dose of dabigatran etexilate
Author:
- 9 October 2012
- journal article
- editorial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 74 (5) , 741-743
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles?British Journal of Clinical Pharmacology, 2012
- Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatranBlood Coagulation & Fibrinolysis, 2012
- New Options in Anticoagulation for Atrial FibrillationNew England Journal of Medicine, 2011
- Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial FibrillationCirculation, 2011
- Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran EtexilateClinical Pharmacokinetics, 2010
- Dabigatran versus warfarin in patients with atrial fibrillation.2009
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly SubjectsClinical Pharmacokinetics, 2008
- Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial FibrillationCirculation, 2007
- The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBritish Journal of Clinical Pharmacology, 2007